By Fineline Cube 
China-based biopharma RemeGen Ltd (HKG: 9995) announced plans to place 10.2% of its issued shares listed in Hong Kong, with a par value of RMB 19 million. The offering is expected to generate gross proceeds of approximately HKD 806 million (USD 103 million). After deducting commissions and estimated expenses, the net proceeds are projected to reach HKD 796 million (USD 102 million). The company intends to use these funds to expand core indications for its flagship product, telitacicept (RC18), including myasthenia gravis and membranous nephropathy, as well as for general corporate purposes.
Share Capital Structure
As of the announcement date, RemeGen’s total issued share capital comprises 544,608,243 shares. This includes 355,027,004 shares listed in mainland China and 189,581,239 shares listed in Hong Kong.-Fineline Info & Tech